
Ocugen (OCGN) • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold OCGN in your mock portfolio yet.
The negative EPS of -0.24 and a PE ratio of -5.04 indicate that Ocugen is currently unprofitable, with losses rather than earnings supporting the stock. In the absence of positive earnings, the equity story is more speculative and dependent on future pipeline or strategic milestones rather than current financial strength.
At $1.21, Ocugen trades below its 200‑day moving average of $1.53, indicating a prevailing downtrend and technical weakness. The 9.7% decline over the last month reinforces negative momentum and suggests ongoing selling pressure rather than a confirmed recovery.
Alternative data show modestly positive operational and engagement signals but not at a scale that clearly changes the investment narrative. Hiring is up meaningfully and social media followings are growing slowly, while web traffic remains relatively low for a listed biotech and does not suggest surging commercial traction.
Overall, Ocugen’s setup appears bearish: the stock is in a downtrend below its 200‑day moving average, and the company is currently unprofitable with negative earnings. While hiring growth and steady social media engagement are mildly constructive, they are not strong enough to offset the combination of weak technicals and lack of profitability.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started